Advertisement

Abdominal Imaging

, Volume 39, Issue 6, pp 1304–1308 | Cite as

Feasible and technical aspects of transcatheter arterial chemoembolization for non-resectable hepatocellular carcinoma using a 3.5-French catheter system

  • Yukinobu Yagyu
  • Masakatsu TsurusakiEmail author
  • Kazutoshi Kamiyama
  • Hajime Kitagaki
  • Takamichi Murakami
Article

Abstract

Purpose

To evaluate the feasibility and technical aspects of transcatheter arterial chemoembolization (TACE) for non-resectable hepatocellular carcinoma (HCC) using a 3.5-French (Fr) catheter system.

Methods

This study included 328 consecutive cases of HCC among 232 patients who underwent TACE procedures using both a 3.5-Fr catheter system and a microcatheter fitted to a 3.5-Fr system between April 2009 and November 2011. We assessed the ability to reach the catheter into the proper hepatic artery (PHA), main hepatic branch, segmental artery, and subsegmental or sub-subsegmental artery. The feasibility was rated according to the following factors: (1) the number of arteries that could be used to reach the target artery/total number of procedures using the 3.5-Fr system, (2) the rate of successful completion of the procedures without changing over to the 4-Fr system and (3) the reasons for changing over the 4-Fr system.

Results

TACE of the PHA (27 sessions), RHA/LHA (103 sessions), segmental (31 sessions), or subsegmental/sub-subsegmental arteries (162 sessions) was performed. The rate of successfully reaching the target artery using the 3.5-Fr system was 93% (306/328 sessions). We were unable to reach the target artery in 22 sessions, including 11/8/3 procedures targeting the sub-subsegmental artery, subsegmental artery, and RHA/LHA, respectively. We changed over to the 4-Fr system in six sessions; therefore, the rate of successful completion of the procedures without changing over to the 4-Fr system was 98% (322/328 sessions).

Conclusions

TACE of the target artery can be successfully performed using the 3.5-Fr system in most patients with HCC.

Keywords

Hepatocellular carcinoma Transcatheter arterial chemoembolization 3.5-Fr catheter system Feasible study 

Notes

Conflict of interest

There is no financial support or relationships that may pose conflict of interest.

References

  1. 1.
    Rahbari NN, Mehrabi A, Mollberg NM, et al. (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253:453–469PubMedCrossRefGoogle Scholar
  2. 2.
    Forner A, Reig ME, de Lope CR, Bruix J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61–74PubMedCrossRefGoogle Scholar
  3. 3.
    Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Cammà C, Schepis F, Orlando A, et al. (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224:47–54PubMedCrossRefGoogle Scholar
  5. 5.
    Kobayashi A, Katsuta Y, Aramaki T, Okumura H (1991) Interrelation between esophageal varices, and systemic and hepatic hemodynamics in male patients with compensated cirrhosis. Jpn J Med 30:318–325PubMedCrossRefGoogle Scholar
  6. 6.
    Mikami K, Osuga K, Nakamura H (2009) Transcatheter arterial chemoembolization for hepatocellular carcinoma using 3 French catheter system. Gan To Kagaku Ryoho 36:959–962PubMedGoogle Scholar
  7. 7.
    Ohuchi Y, Kaminou T, Hashimoto M, et al. (2011) Transfemoral approach using a 3.5-French catheter system for use in transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: technical assessment. Hepatogastroenterology 58:916–921PubMedGoogle Scholar
  8. 8.
    Matsuo N, Uchida H, Nishimine K, et al. (1993) Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumour effect and influence on normal tissue. J Vasc Interv Radiol 4:543–549PubMedCrossRefGoogle Scholar
  9. 9.
    Uchida H, Ohishi H, Matsuo N, et al. (1990) Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Interv Radiol 13:140–145CrossRefGoogle Scholar
  10. 10.
    Matsui O, Kadoya M, Yoshikawa J, et al. (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83PubMedCrossRefGoogle Scholar
  11. 11.
    Shiozawa S, Tsuchiya A, Endo S, et al. (2003) Transradial approach for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: comparison with conventional transfemoral approach. J Clin Gastroenterol 37:412–417PubMedCrossRefGoogle Scholar
  12. 12.
    Shiozawa S, Tsuchiya A, Kim DH, et al. (2007) Transradial approach for transcatheter arterial chemoembolization in patients with unresectable and recurrent hepatocellular carcinoma–a comparison with a conventional transfemoral approach. Gan To Kagaku Ryoho 34:2096–2098PubMedGoogle Scholar
  13. 13.
    Watanabe S, Minami A, Nishioka M, Ohkawa M, Koui F (1997) Left brachial approach for transcatheter arterial embolization therapy in patients with hepatocellular carcinoma. Dig Dis Sci 42:47–58PubMedCrossRefGoogle Scholar
  14. 14.
    Murdaco F, Auerbach M, Berdoff RL, Goldberg E (1983) Consumptive coagulopathy secondary to a groin hematoma: an unusual complication of percutaneous transfemoral catheterization. Catheter Cardiovasc Diagn 9:75–77CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Yukinobu Yagyu
    • 1
  • Masakatsu Tsurusaki
    • 1
    • 2
    Email author
  • Kazutoshi Kamiyama
    • 2
  • Hajime Kitagaki
    • 2
  • Takamichi Murakami
    • 1
  1. 1.Department of Radiology, Faculty of MedicineKinki UniversityOsakaJapan
  2. 2.Department of Radiology, School of MedicineShimane UniversityIzumoJapan

Personalised recommendations